Orally active growth hormone secretagogues: state of the art and clinical perspectives

References

• Bowers C Y, Chang J, Momany F, Folkers K. Effects of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. Molecular Endocrinology, I Macintyne. Elsevier, Amsterdam 1977; 287–92
   Google Scholar
• Momany F A, Bowers C Y, Reynolds G A, Hong A, Newlander K. Conformational energy studies and in vitro and in vivo activity data on active GH releasing peptides. Endocrinology 1984; 114: 1531–6
   PubMedGoogle Scholar
• Bowers C Y, Veeraragavan K, Sethumadhavan K. Atypical growth hormone releasing peptides. Growth Hormone II, Basic and Clinical Aspects, B B Bercu, R F Walker. Springer-Verlag, New York 1993; 203–22
   Google Scholar
• Deghenghi R, Bontignon F, Luoni M, Grilli R, Guidi M, Locatelli V. Small peptides as potent releasers of growth hormone. J Pediatr Endocrinol Metab 1995; 8: 311–3
   PubMedGoogle Scholar
• Korbonits M, Grossman A B. Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release. Trends Endocrinol Metab 1996; 6: 43–9
   Google Scholar
• Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol 1997; 136: 445–60
   PubMed Web of Science ®Google Scholar
• Jacks T, Smith R, Judith F, et al. MK-0677, a potent novel, orally-active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology 1996; 137: 5284–9
   PubMedGoogle Scholar
• Copinschi G, Van Onderbergen A, L'Hermite-Baleriaux M, et al. Effects of 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab 1996; 81: 2776–82
   PubMed Web of Science ®Google Scholar
• Chapman I M, Bach M A, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996; 81: 4249–57
   PubMed Web of Science ®Google Scholar
• Ghigo E, Arvat E, Gianotti L. ct al. Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man. J Clin Endocrinol Metab 1994; 78: 693–8
   PubMed Web of Science ®Google Scholar
• Jacks T, Hickey G, Judith F, et al. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-I, ACTH, Cortisol, prolactin, insulin, and thyroxine levels in beagles. J Endocrinol 1994; 143: 399–406
   PubMedGoogle Scholar
• Bowers C Y, Reynolds G A, Durham D, Barrera C M, Pezzoli S S, Thorner M O. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990; 70: 975–82
   PubMedGoogle Scholar
• Gcrtz B J, Barrett J S, Eisenhandler R, et al. Growth hormone response in man to L-692,429, a novel non peptide mimic of growth hormone-releasing peptide-6. J Clin Endocrinol Metab 1993; 77: 1393–7
   PubMedGoogle Scholar
• Aloi J A, Gertz B J, Hartman M L, et al. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. J Clin Endocrinol Metab 1994; 79: 943–9
   PubMedGoogle Scholar
• Korbonits M, Trainer P J, Besser G M. The effect of an opiate antagonist on the hormonal changes induced by Hexarelin. Clin Endocrinol 1995; 43: 365–71
   PubMedGoogle Scholar
• Locke W, Kirgis H D, Bowers C Y, Abdo A A. Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sci 1995; 56: 1347–52
   PubMed Web of Science ®Google Scholar
• Frieboes R M, Murck H, Maier P, Schier T, Holsboer F, Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and Cortisol release in normal man. Neuroendocrinology 1995; 61: 584–9
   PubMedGoogle Scholar
• Howard A D, Feighner S D, Cully D F, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974–7
   PubMed Web of Science ®Google Scholar
• Codd E E, Shu A YL, Walker R F. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 1989; 28: 1139–44
   PubMed Web of Science ®Google Scholar
• Muccioli G, Ghe C, Ghigo M C, et al. GHRP receptors in pituitary, central nervous system and peripheral human tissues. J Endocrinol Invest 1997; 20(Suppl 4)52
   PubMedGoogle Scholar
• De Gennaro Colonna V, Rossoni G, Bernareggi M, Muller E E, Berti F. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin. Eur J Pharmacol 1997; 334: 201–7
   PubMedGoogle Scholar
• Badger T M, Millard W Y, McCormik G F, Bowers C Y, Martin J B. The effects of growth hormone (GH)-releasing peptides on GH secretion in perifused pituitary cells of adult male rats. Endocrinology 1984; 115: 1432–8
   PubMedGoogle Scholar
• Sartor O, Bowers C Y, Chang D. Parallel studies of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 and human pancreatic growth hormone-releasing factor-44-NH2 in rat primary pituitary cell monolayer culture. Endocrinology 1985; 116: 952–7
   PubMedGoogle Scholar
• Cheng K, Chan W WS, Barreto A, Convey E M, Smith R G. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′,5′-monophosphate accumulation in rat primary cell culture. Endocrinology 1989; 124: 2791–8
   PubMed Web of Science ®Google Scholar
• Bowers C Y, Sartor A O, Reynolds G A, Badger T M. On the action of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991; 128: 2027–35
   PubMedGoogle Scholar
• Goth M I, Lyons C E, Canny B Y, Thorner M O. Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 1992; 130: 939–44
   PubMed Web of Science ®Google Scholar
• Locatelli V, Grilli R, Torsello A, Cella S G, Wehrenberg W B, Muller E E. Growth hormone-releasing hexapeptide is a potent stimulator of growth hormone gene expression and release in the growth hormone-releasing hormone-deprived infant rat. Pediatr Res 1994; 36: 169–74
   PubMedGoogle Scholar
• Malozowski S, Hao E N, Ren S G, et al. Growth hormone (GH) responses to the hexapeptide GH-releasing peptide and GH-releasing hormone (GHRH) in the cynomologus macaque: evidence for non-GHRH-mediated responses. J Clin Endocrinol Metab 1991; 73: 314–7
   PubMedGoogle Scholar
• Clark R G, Carisson M S, Trojnar J, Robinson I CAF. The effects of a growth hormone-releasing peptide and growth hormone-releasing factor in conscious and anaesthetized rats. J Neuroendocrinol 1989; 1: 252–5
   Google Scholar
• Walker R F, Yang A W, Masuda R, Hu C S, Bercu B B. Effects of growth hormone releasing peptides on stimulated growth hormone secretion in old rats. Growth Hormone II, Basic and Clinical Aspects, B B Bercu, R F Walker. Springer-Verlag, New York 1993; 167–92
   Google Scholar
• Cella S, Locatelli V, Poratelli M, et al. Hexarelin, a potent GHRP analogue: interaction with GHRH and clonidine in young and aged dogs. Peptides 1995; 16: 81–6
   PubMedGoogle Scholar
• Fairhall K M, Mynett A, Robinson I CAF. Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. J Endocrinol 1995; 144: 555–60
   PubMedGoogle Scholar
• Mallo F, Alvarez C V, Benitez L, Burguera B, Coya R, Casanueva F F. Regulation of His-dTRP-Ala-Trp-dPhe-Lys-NH2 (GHRP6)-induced GH secretion in the rat. Neuroendocrinology 1992; 57: 247–51
   Google Scholar
• Fletcher T P, Thomas G B, Willoughby J O, Clarke I J. Constitutive growth hormone secretion in sheep after hypothalamopituitary disconnection and the direct in vivo pituitary effect of growth hormone releasing peptide 6. Neuroendocrinology 1994; 60: 76–86
   PubMedGoogle Scholar
• Hickey G J, Drisko J, Faidley T, et al. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. J Endocrinology 1996; 148: 371–80
   PubMedGoogle Scholar
• Conley L K, Teik J A, Deghenghi R, et al. Mechanism of action of Hexarelin and GHRP-6: analysis of the involvement of GHRH and somatostatin in the rat. Neuroendocrinology 1995; 61: 44–50
   PubMedGoogle Scholar
• Dickson S L, Luckman S M. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Endocrinology 1997; 138: 771–7
   PubMed Web of Science ®Google Scholar
• Guillame V, Magnam E, Cataldi M, et al. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology 1994; 135: 1073–6
   PubMedGoogle Scholar
• Sartor O, Bowers C Y, Reynolds G A, Momany F A. Variables determining the growth hormone response of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the rat. Endocrinology 1985; 117: 1441–7
   PubMedGoogle Scholar
• Muruais J, Penalva A, Dieguez C, Casanueva F F. Influence of endogenous cholinergic tone and alpha-adrenergic pathways on growth hormone responses to His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the dog. Endocrinol 1993; 138: 211–8
   Google Scholar
• Fairhall K M, Mynett A, Smith R G, Robinson I CAF. Consistent GH responses to repeated injections of GH-releasing hexapeptide (GHRP-6) and the non-peptide GH secretagogue, L-692,585. Endocrinol 1995; 145: 417–26
   Google Scholar
• Adams E F, Petersen B, Lei T, Hunchfelder M, Fanlbusch R. The growth hormone secretagogue, L-692,429, induces phosphatidylinositol hydrolysis and hormone secretion by human pituitary tumors. Biochem Biophys Res Commun 1995; 214: 454–60
   PubMedGoogle Scholar
• Thomas G B, Fairhall K M, Robinson I CAF. Activation of the hypothalamo-pituitary-adrenal axis by the growth hormone (GH) secretagogue, GH-releasing peptide-6, in rats. Endocrinology 1997; 138: 1585–91
   PubMed Web of Science ®Google Scholar
• de Keyzer Y, Lenne F, Bertagna X. Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors. Eur J Endocrinol 1997; 137: 715–8
   PubMedGoogle Scholar
• Mazza E, Ghigo E, Goffi S, et al. Effect of the potentiation of cholinergic activity on the variability in individual GH response to GHRH. J Endocrinol Invest 1989; 12: 795–9
   PubMedGoogle Scholar
• Penalva A, Pombo M, Carballo A, Barreiro J, Casanueva F F, Dieguez C. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6. Clin Endocrinol (Oxf) 1993; 38: 87–91
   PubMedGoogle Scholar
• Bowers C Y. GH releasing peptides. Structure and kinetics. J Pediatr Endocrinol 1993; 6: 21–31
   PubMed Web of Science ®Google Scholar
• Ghigo E, Arvat E, Rizzi G, et al. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is mantained after short-term oral pretreatment with the hexapeptide in normal aging. Eur J Endocrinol 1994; 131: 1–4
   Google Scholar
• Arvat E, Gianotti L, Grottoli S, et al. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of Hexarelin in elderly subjects. J Clin Endocrinol Metab 1994; 79: 1440–3
   PubMedGoogle Scholar
• Bellone J, Airnaretti G, Bartolotta E, et al. Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, before and during puberty. J Clin Endocrinol Metab 1995; 80: 1090–4
   PubMedGoogle Scholar
• Ghigo E, Arvat E, Gianotti L, et al. Short term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the GH responsiveness in human aging. Eur J Endocrinol 1996; 135: 407–12
   PubMedGoogle Scholar
• Chatelain P, Claris O, Lapillonne A, Dimayo M, Salle B. Fetal and neonatal somatotroph function. Front Paediatr Neuroendocrinal 1994; 20: 127–30
   Google Scholar
• Loche S, Colao A, Cappa M, et al. The growth hormone response to Hexarelin in children: reprodicibility and effect of sex steroids. J Clin Endocrinol Metab 1997; 82: 861–4
   PubMedGoogle Scholar
• Arvat E, Gianotti L, Broglio F, et al. Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in postmenopausal women. Eur J Endocrinol 1997; 136: 483–7
   PubMedGoogle Scholar
• Penalva A, Carballo A, Pombo M, Casanueva F F, Dieguez C. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man. J Clin Endocrinol Metab 1993; 76: 168–71
   PubMedGoogle Scholar
• Arvat E, Gianotti L, Di Vito L, et al. Modulation of growth hormone-releasing activity of Hexarelin in man. Neuroendocrinology 1995; 61: 51–6
   PubMedGoogle Scholar
• Arvat E, Gianotti L, Ramunni J, et al. Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man. J Endocrinol Invest 1996; 19: 25–9
   PubMedGoogle Scholar
• Gertz B J, Sciberras D G, Yogendran L, et al. L-692,429, a nonpeptide growth hormone (GH) secretagogue reverses glucocorticoid suppression of GH secretion. J Clin Endocrinol Metab 1994; 79: 745–9
   PubMedGoogle Scholar
• Maccario M, Arvat E, Procopio M, et al. Metabolic modulation of the growth-hormone-releasing activity of Hexarelin in man. Metabolism 1995; 44: 134–8
   PubMedGoogle Scholar
• Massoud A F, Hindmarsh P C, Brook C G. Hexarelin induced growth hormone release is influenced by exogenous growth hormone. Clin Endocrinol 1995; 43: 617–21
   PubMedGoogle Scholar
• Arvat E, Di Vito L, Gianotti L, et al. Mechanisms underlying the negative growth hormone (GH) auto-feedback on the GH-releasing effect of Hexarelin in man. Metabolism 1997; 46: 83–8
   PubMedGoogle Scholar
• Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva F F. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995; 80: 942–7
   PubMed Web of Science ®Google Scholar
• Pombo M, Barreiro J, Penalva A, Peino R, Dieguez C, Casanueva F F. Absence of growth hormone (GH) secretion after the administration of either GH releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. J Clin Endocrinol Metab 1995; 80: 3180–4
   PubMedGoogle Scholar
• Loche S, Cambiaso P, Merola B, et al. The effect of Hexarelin on growth hormone (GH) secretion in patients with GH deficiency. J Clin Endocrinol Metab 1995; 80: 2692–6
   PubMedGoogle Scholar
• Jaffe C A, Ho P J, Demott-Friberg R, Bowers C Y, Barkan A L. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab 1993; 77: 1641–7
   PubMedGoogle Scholar
• Huhn W C, Hartman M L, Pezzoli S S, Thorner M O. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab 1993; 76: 1202–8
   PubMedGoogle Scholar
• DeBell W K, Pezzoli S S, Thorner M O. Growth hormone (GH) secretion during continous infusion of GH-releasing peptide: partial response attenuation. J Clin Endocrinol Metab 1991; 72: 1312–6
   PubMedGoogle Scholar
• Laron Z. Growth hormone secretagogues. Drugs 1995; 50: 595–601
   PubMedGoogle Scholar
• Arvat E, di Vito L, Maccagno B, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and Cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides 1997; 18: 885–91
   PubMedGoogle Scholar
• Arvat E, Ramunni J, Bellone J, et al. The GH, prolactin, ACTH and Cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations. Eur J Endocrinol 1997; 137: 635–42
   PubMedGoogle Scholar
• Arvat E, Maccagno B, Ramunni J, et al. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or Hexarelin, a synthetic hexapetide, in man. J Endocrinol Invest 1997; 20: 122–7
   PubMedGoogle Scholar
• Ciccarelli E, Grottoli S, Razzore P, et al. Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyper-prolactinemia patients. Clin Endocrinol 1996; 44: 67–71
   PubMedGoogle Scholar
• Arvat E, Maccagno B, Ramunni J, et al. Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and Cortisol secretion in humans. Neuroendocrinology 1997; 66: 432–8
   PubMedGoogle Scholar
• Ghigo E, Arvat E, Ramunni J, et al. Adrenocorticotropin-and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997; 82: 2439–44
   PubMedGoogle Scholar
• Orth D N. Corticotropin-releasing hormone in humans. Endocr Rev 1992; 13: 164–91
   PubMed Web of Science ®Google Scholar
• Arvat E, Maccagno B, Ramunni J, et al. Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortison and GH secretion in humans. Neuroendocrinology, in press
   Google Scholar
• Renner U, Brockmeier S, Strasburger C J, et al. Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: interaction with GH-releasing hormone, thyrotropin-releasing hormone, and octreotide. J Clin Endocrinol Metab 1994; 78: 1090–6
   PubMedGoogle Scholar
• Popovic V, Damjanovic S, Micic D, Petakov M, Dieguez C, Casanueva F F. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6. J Clin Endocrinol Metab 1994; 79: 456–60
   PubMedGoogle Scholar
• Alster D K, Bowers C Y, Jaffe C A, Ho P J, Barkan A L. The growth hormone (GH) response to GH-releasing peptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2), GH-releasing hormone, and thyrotropin-releasing hormone in acromegaly. J Clin Endocrinol Metab 1993; 77: 842–5
   PubMedGoogle Scholar
• Giustina A, Bonfani C, Licini M, Ragni G, Stefana B. Hexarelin, a novel GHRP-6 analog, stimulates growth hormone (GH) release in a GH-secreting rat cell line (GH1) insensitive to GH-releasing hormone. San Francisco, CA 1996; 288, Abstracts of the 10th International Congress of Endocrinology; 1996 June 12–15
   Google Scholar
• Popovic V, Micic D, Damjanovic S, et al. Evaluation of pituitary GH reserve with GHRP-6. J Pediatr Endocrinol Metab 1996; 9: 289–98
   PubMedGoogle Scholar
• Ramos-Dias J C, Pimentel Filho F, Reis A F, Lengyel A MJ. Different growth hormone (GH) responses to GH-releasing peptide and GH-releasing hormone in hyperthyroidism. J Clin Endocrinol Metab 1996; 81: 1343–6
   PubMedGoogle Scholar
• Van den Berghe G, de Zegher F, Veldhuis J D, et al. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 1997; 82: 590–9
   PubMed Web of Science ®Google Scholar
• Bellone J, Ghizzoni L, Aimaretti G, et al. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol 1995; 133: 425–9
   PubMed Web of Science ®Google Scholar
• Pombo M, Barreiro J, Penalva A, Mallo F, Casanueva F F, Dieguez C. Plasma growth hormone response to growth hormone releasing hexapeptide (GHRP-6) in children with short stature. Acta Paediatr 1995; 84: 904–8
   PubMedGoogle Scholar
• Pihoker C, Middleton R, Reynolds G A, Bowers C Y, Badger T M. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in childen of short stature. J Clin Endocrinol Metab 1995; 80: 2987–92
   PubMed Web of Science ®Google Scholar
• Leal-Ccrro A, Garcia E, Astorga R, Casanueva F F, Dieguez C. Growth hormone (GH) responses to the combined administration of GH-releasing peptide 6 in adults with GH deficiency. Eurr J Endocrinol 1995; 132: 712–5
   PubMedGoogle Scholar
• Chapman I M, Pescovitz O H, Treep T, et al. Oral administration of the GHRP-mimetic MK-0677 stimulates the GH/IGF-1 axis in GH deficient adults. San Francisco, CA 1996; 769, Abstracts of the 10th International Congress of Endocrinology;
   Google Scholar
• Thorner M O, Hartman M L, Gaylinn B D. Current status of therapy with growth hormone-releasing neuropeptides. Frontiers in Paediatric Neuroendocrinology, M O Savage, J Bourgulgon, A B Grossman. Blackwell, Oxford 1994; 161–7
   Google Scholar
• Cordido F, Peino R, Penalva A, Alvarez C V, Casanueva F F, Dieguez C. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. J Clin Endocrinol Metab 1996; 81: 914–8
   PubMed Web of Science ®Google Scholar
• Grottoli S, Maccario M, Procopio M, et al. Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity. Eur J Endocrinol 1996; 135: 678–82
   PubMedGoogle Scholar
• Edwards C A, Dieguez C, Scanlon M F. Effects of hypothyroidism, tri-iodothyronine and glucocorticoids on growth hormone responses to growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. J Endocrinol 1989; 121: 31–6
   PubMed Web of Science ®Google Scholar
• Leal-Cerro A, Pumar A, Garcia-Garcia E, Dieguez C, Casanueva F F. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome. Clin Endocrinol 1994; 41: 649–54
   PubMedGoogle Scholar
• de Boer H, Blok G J, Poo-Snijders C, van der Veen E A. Diagnosis of growth hormone deficiency in adults. Lancet 1994; 343: 1645–6
   PubMedGoogle Scholar
• Rudman D, Feller A G, Nagraj H S. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1–6
   PubMed Web of Science ®Google Scholar
• Ross J RJM, Chew S L. Acquired growth hormone resistance. Eur J Endocrinol 1995; 132: 655–60
   PubMed Web of Science ®Google Scholar
• Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 100–3
   Google Scholar